Exagen (NASDAQ:XGN - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $13.85 million for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.
Exagen Trading Up 3.2 %
Shares of XGN stock traded up $0.10 during trading hours on Friday, hitting $3.23. The company had a trading volume of 19,031 shares, compared to its average volume of 164,646. Exagen has a fifty-two week low of $1.30 and a fifty-two week high of $6.22. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The company's fifty day moving average is $3.86 and its 200 day moving average is $3.56. The stock has a market capitalization of $56.97 million, a PE ratio of -3.44 and a beta of 1.40.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $8.00 price objective on shares of Exagen in a report on Monday, January 13th. Canaccord Genuity Group lifted their price objective on Exagen from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Finally, William Blair reissued an "outperform" rating on shares of Exagen in a report on Wednesday, November 13th.
Get Our Latest Research Report on Exagen
Exagen Company Profile
(
Get Free Report)
Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Featured Stories
Before you consider Exagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.
While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
